explore -WSS

explore

author：entertainment 2025-09-28 00:49:16 - browse：47

The Dr. Gary B. and Pamela S. Williams Tower in Summa Health System's Akron Campus — Summa Health

General Catalysts’s grand vision for a venture capital-owned hospital system seamlessly blending AI and tech into everyday appointments and rewarding staff for keeping patients healthy might sound alluring. But the firm’s bold experiment is facing hurdles even before it has started as the community served by the health system it hopes to buy is pushing back.

The Health Assurance Transformation Corp., a General Catalyst entity known as HATCo, unveiled plans last month to acquire Akron safety net provider Summa Health. But since the announcement, residents and local officials have raised questions about who the deal benefits, and who gets left behind.

On Thursday, the Mayor of Akron plans to press HATCo’s chief executive, Marc Harrison, who previously led Intermountain Health, on whether his plan is a profit play or a longer-term investment in the community. At the forefront are citizens’ concerns that the deal will drive up costs, eliminate jobs, reduce the quality of care or even shutter one of just two major hospital systems in the area, about a fifth of whose patients are on Medicaid.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： European regulators recommend Amylyx's ALS drug be rejected

WSS

Morphosys mixed study results for blood cancer drug

European regulators recommend Amylyx's ALS drug be rejected

European regulators consider appeal over Amylyx ALS drug

Life sciences deals on track to hit lowest point since 2017

Weight loss drug costs may need more research, senator suggests

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

focus

explore

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

Buoyed by wins on obesity, Novo Nordisk eyes heart disease

Walensky prepares to leave CDC — and Congress — behind

Peter Marks talks Operation Warp Speed for Rare Diseases

The cancer drug shortage isn’t new — and neither are the solutions

Wellcome Trust names Røttingen as its new CEO

Drug repurposing or repositioning? The language matters

Cancer cells are shown to suck energy source from immune cells

How to save PrEP access — and even expand it

Eight reasons why you should get an updated Covid vaccine

entertainment

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Morphosys mixed study results for blood cancer drug

Peter Marks talks Operation Warp Speed for Rare Diseases

Astellas still sees hope in its gene therapy after four deaths

Massive project maps cells in human brain in unprecedented detail

Wegovy, Zepbound and weight loss drugs that preserve muscle

hotspot

explore

focus

hotspot